Our Pipeline

Leading the Way in Cell Therapy

Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors.

PROGRAM

PHASE

  • PHASE 1
  • PHASE 2
  • PHASE 3
  • FILED

Axicabtagene ciloleucel

  • PHASE 3

Trial:

ZUMA-22

 

2L+ high-risk follicular lymphoma

Axicabtagene ciloleucel

  • PHASE 3

Trial:

ZUMA-23

 

1L high-risk large B-cell lymphoma

Axicabtagene ciloleucel

  • PHASE 2

Trial:

ZUMA-24

 

2L large B-cell lymphoma outpatient

Brexucabtagene autoleucel

  • PHASE 2

Trial:

ZUMA-4

 

Pediatric acute lymphocytic leukemia

CLINICAL TRIALS

Brexucabtagene autoleucel

  • PHASE 2

Trial:

ZUMA-25

 

Basket (rare B-cell malignancies)

CAR-T ddBCMA (Kite-772)1

  • PHASE 2

Trial:

iMMagine-1

 

Relapsed/refractory multiple myeloma

CLINICAL TRIALS

CLL-1 (KITE-222)

  • PHASE 1

Trial:

KITE-222

 

Relapsed/refractory acute myeloid leukemia

CLINICAL TRIALS

CD19/20 bicistronic (KITE-363)

  • PHASE 1

Trial:

KITE-363

 

3L+ diffuse large B-cell lymphoma

CLINICAL TRIALS

1Global strategic collaboration to co-develop and co-commercialize with Arcellx.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized.

Some of the content on this page is not intended for users outside the US.